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Summary
We characterized the pyruvate carboxylase (PC) gene by
PCR amplification, subcloning, and sequencing. The
coding region has 19 exons and 18 introns spanning
∼16 kb of genomic DNA. Screening both the cDNA and
the gene of individuals with the simple A form of PC
deficiency revealed an 1828GrA missense mutation in
11 Ojibwa and 2 Cree patients and a 2229GrT trans-
version mutation in 2 brothers ofMicmac origin. Carrier
frequency may be as high as 1/10 in some groupings.
The two point mutations are located in a region of ho-
mology conserved among yeast, rat, and human PC, in
the vicinity of the carboxylation domain of the enzyme.
These data provide the first characterization of the hu-
man PC gene structure, the identification of common
pathogenic mutations, and the demonstration of a foun-
der effect in the Ojibwa and Cree patients.
Introduction
Pyruvate carboxylase (PC) is a nuclear-encoded mito-
chondrial enzyme that catalyzes the ATP-driven for-
mation of oxaloacetate from pyruvate and HCO3

(Crabtree et al. 1972; Lee and Davis 1979). In mammals,
the native enzyme is a homotetramer with each subunit
(molecular weight 127,000) containing a covalently
bound molecule of biotin, as well as binding sites for
pyruvate, ATP, HCO3
, and acetyl CoA (Wood and Bar-
den 1977). PC becomes active in conditions in which
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fatty acids are mobilized and are generating acetyl-CoA
(Keech and Utter 1963). Thus, acetyl-CoA is a powerful
allosteric activator of human PC, which is virtually in-
active without bound acetyl-CoA (Keech and Barritt
1967; Lim et al. 1988). In mammals, PC is located solely
in the mitochondrial matrix (Walter and Anabitarte
1973). The roles of PC in intermediate metabolism are
tissue specific. In gluconeogenic tissue (liver and kidney)
it catalyzes the first step in the synthesis of glucose from
pyruvate, whereas in lipogenic tissue (liver, adipose, lac-
tating mammary gland, and adrenal gland) it partici-
pates in the export of acetyl groups, as citrate, from the
mitochondria to the cytosol. In CNS tissues, PC partic-
ipates in the replenishment of neurotransmitter pools of
glutamate, GABA, and aspartate (Shank et al. 1985).
Information from the rat gene indicates that two sepa-
rate transcripts generated from different promoters 10
kb apart on the same gene are produced with identical
coding regions (Jitrapakdee et al. 1997). These two tran-
scripts have, in liver and kidney, 5′ UTR sequences dif-
ferent from those in brain and heart.
PC deficiency in individuals occurs in three distinct
forms: a milder form, A, in which the presenting features
are lactic acidemia and psychomotor retardation; a more
severe form, B, in which severe neonatal lactic acidosis,
hyperammonemia, and abnormal redox state result in
death at age !3 mo (Robinson 1995); and a third form,
which appears to be relatively benign, causing only mild
lacticacidemia (Van Coster et al. 1991). Molecular char-
acterization of the A and B forms, by use of [3H]-biotin
labeling, immunoprecipitation of [35S]-labeled proteins,
[35S]-streptavidin labeling, and northern blot analysis,
showed that those with the A form of PC deficiency had
a biotin-containing 125-kD protein corresponding to PC
(hereafter, this form is designated “CRM”), whereas
those with the B form were missing either biotinylated
PC protein (hereafter, this form is designated “CRM”)
and/or PC mRNA (Robinson et al. 1984, 1987; Rob-
inson 1989). In the CRM patients, the lack of intra-
cellular aspartate and oxaloacetate compromises both
the synthetic and the anaplerotic pathways that require
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Figure 1 DNA sequence from a small region within the PC gene,
showing the GrA transition at nucleotide 1828.A,Wild-type sequence
from a normal Ojibwa. B, Sequence from a PC-deficient Ojibwa ho-
mozygous for the mutation.
Table 1
Clinical Features of CRM PC Deficiency in a Cree
Population and in an Ojibwa Population, in
Northwestern Ontario and Manitoba
Category Distribution or Measurement
Patients 11 Males, 6 females, 11 families
Age at presentation At birth for 7, at 1–8.5 mo for 10
Presenting signs Metabolic acidosis in 10, seizures
in 5, respiratory distress in 4,
pneumonia in 3, hypotonia in 3
Clinical course Frequent lactic acidosis/severe de-
velopmental delay and muscu-
lar hypotonia in 17, seizures in
8, hypoglycemia in 4, other
CNS involvement (clonus or
athetosis) in 4
Outcome 11 Deaths at 3 mo–4.75 years, 6
survivors 3 mo–19 years old
Lactate/pyruvate
(control value
10–25)
!15 in 4, 16–25 in 7, 125 in 5
b-OH-butyrate/ace-
toacetate (con-
trol value
.5–2.5)
.3–1.6 in 6
PC activity in fi-
broblasts (con-
trol value .4–1.4
nmol/min/mg
protein)
1%–4% in 12
PC activity. In CRM patients, the gene is expressed in
the form of a biotin-containing protein that possesses
enough residual catalytic activity to sustain the ana-
plerotic functions of PC (Robinson et al. 1984).
The Canadian Indian population is strongly repre-
sented in our study of CRM PC deficiency, there being
cases in the Micmac, Cree, and Ojibwa. This common
linguistic group is derived from a founder group in
southern Ontario ∼300 B.C. It has been suggested that
there could be one or more disease-causing mutations
in the PC gene that are unique to the “Algonkian-speak-
ing peoples” of North America (Robinson 1989). Hav-
ing described the cDNA (MacKay et al. 1994; Wexler
et al. 1994), we began work on the gene structure of the
coding region, so that we could define these inherited
defects.
Material and Methods
Patient Samples
Cultured fibroblast cell lines from forearm-skin bi-
opsies were obtained, with informed consent of parents,
from patients with a clinical diagnosis of PC deficiency.
Diagnosis was based on a PC enzyme assay (Robinson
et al. 1985) modified from the method of Utter and
Keech (1963), immunoprecipitation of [35S]-labeled pro-
teins, [3H]-biotin labeling, and northern blot analysis
(Robinson et al. 1983, 1984, 1987). Table 1 lists several
of the clinical features presented by the Ojibwa and Cree
from Ontario and Manitoba who have the CRM form
of PC deficiency.
Cell Lines and DNA Isolation
Fibroblasts from 5 normal Ojibwa and from 15 PC-
deficient patients (11 Ojibwa, 2 Cree, and 2 Micmac)
exhibiting the simple A phenotype were used to prepare
genomic DNA. Cells were grown at 37C to 100% con-
fluency in a minimal essential medium/2# glucose cul-
ture medium containing 10% FCS and 1% antibiotic
(streptomycin/penicillin). Genomic DNA was extracted
by a modified version of the method of Miller et al.
(1988). The absorbance (260 nm) was assessed for each
sample, and each sample subsequently was diluted to a
concentration of 0.100 mg/ml.
Genomic Characterization of the PC Gene
DNA from normal human liver or brain was amplified
into 18 different fragments spanning the 16 kb of PC
genomic DNA, by use of PC-specific primers (table 2)
derived from its cDNA sequence (MacKay et al. 1994).
Each PCR product was isolated and subcloned into the
pCR 2.1 (3.9 kb) vector, by use of the TA subcloning
kit (Invitrogen) designed for PCR products. The nucle-
otide sequences for several clones of the subcloned frag-
ments were determined by the dideoxynucleotide
method (Sanger 1977), by use of the T7DNA sequencing
kit (Pharmacia Biotech). The location and sequence of
the introns were identified by alignment of the genomic
sequences to the cDNA sequence of human kidney PC
(MacKay et al. 1994; Wexler et at. 1994). Table A1, in
the Appendix, documents the corrections that, on the
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Table 2
Sequences of Oligonucleotides (5′r3′) from PC cDNA That Were Used to Amplify and Sequence PC Introns
Intron Forward Primer Reverse Primer
1 TAAGCCTATCAAGAAGTAATG CATCAGCTTTCTGCCTGTGCAT
2 GGAGCAGGACACAGGGCAGATG GGGCTTCCACCTTGTCTCCCAT
3 CGGTTTATTGGTCCAAGCCCA GATGATGGGGAAGCCGTAGGT
4 ATCACGTCCCTGCATGAGGCC TGGCTTCTCGATGAACTTCTC
5 TATGAGGAGTTGGAAGAGAATTA GTTTAGCGAGTTTCACAGAGTCGC
6 GCGACTCTGTGAAACTCGCTAAAC CTCTGTGACCGTGTGCTCCACC
7 GGTG GAGCACACGGTCACAGAG GCCGGTGTCCGGCTGGAACGT
8 ACGTTCCAGCCGGACACCGGC GGCGAGATGACGGCTCCT
9 ATGAGCAGGGCCCTTGCGGAGTTCCGTGTC GAGCACATTCTGCAGGAAGGCGATGTTGGT
10 CAGTTCCTGGCAGGCACTGTG CTGCAGGAAGGCGATGTTGGTCT
11 CAGTTCCTGGCAGGCACTGTG CGGGTGGTTCCGCACAGCTCGAGC
12 GCTCGAGCTGTGCGGAACCACCCG CTCCCGGAGCTCCTGCAG
13 GGCATGGATGTCTTCCGTGTG CTGGGCACAGGCCAGCATGGC
14 ATGACTTCACAGCCCAGCATG GTACAGTCCCCGAGCCCCCTC
15 AACCTGCACTTCGAGGCCCAC GGACAGCTCTTCCGCCTGAGC
16 GCTCAGGCGGAAGAGCTGTCC CCCATGCCGGTCTACCAGCTC
17 TTCAAGGACTTCACTGCCACC GGACCGCAGCTGCCCATTGAG
18 CTCAATGGGCAGCTGCGGTCC CGCCCCGATCTGGCCCTTCAC
Table 3
Exon/Intron Splice-Junction Sequences of the Gene for Human PC
Exon
Numbera
Size
(kb)
Intron
Number
Size
(kb)
SEQUENCE
Exon Intron Exon
1 .136 1 .153 AGA G; Gly (46) gtgagcac.....ccctctag Gly (46); GT GAG
2 .185 2 .201 GCC AAG; Lys (107) gtgagccc.....accgtcag Glu (108); GAG AAC
3 .166 3 .106 GCG G; Gly (163) gtgaatat.....cccaacag Gly (163); GT GTT
4 .146 4 .153 TAC GAG; Glu (211) gtgagtga.....cctcgcag Glu (211); GAG CTG
5 .119 5 .480 TTG GG; Gly (251) gtgagcgg.....cctcccag Gly (251); G GAC
6 .151 6 1.4 AAA CAG; Gln (301) gtgaaggg.....cgccacag Val (302); GTG GGC
7 .119 7 2.4 ACC GA; Asp (341) gtgagtgt.....ccctacag Asp (341); C GTA
8 .163 8 2.2 ATT GAG; Glu (395) gtgggcgg.....cttcccag Val (396); GTG TTC
9 .183 9 3.0 GTG AAG; Lys (456) gtgagagg.....ccctgcag Thr (457); ACC AAC
10 .144 10 .399 TAC CTC; Leu (504) ggcctggc.....ctccccag Gly (505); GGC CAT
11 .091 11 .084 ATA G; Gly (535) gtaggtga.....taccctag Gly (535); GC CCG
12 .222 12 .770 GGA G; Gly (609) gtaggctg.....ctgtgcag Gly (609); GA GCC
13 .400 13 .105 ATC AAG; Lys (741) gtgcctgg.....tcccccag Asp (742); GAC ATG
14 .250 14 .207 ACA G; Glu (825) gtaggaag.....ccctgcag Glu (825); AG GTG
15 .245 15 .150 ATC AAG; Lys (906) gtgagccc.....ctcctcag Val (907); GTG ACG
16 .180 16 .079 TCT AAG; Lys (966) gtagggaa.....ctccccag Val (967); GTA CTG
17 .249 17 .600 TTT GAG; Glu (1049) gtcagtgg.....ccctgcag Val (1050); GTG GAG
18 .141 18 .081 ATG AAG; Lys (1096) gtattgtc.....gtcttcag Glu (1097); GAG ATG
19 .249 GAG TGA; Glu stop (1178)
a Listed in 5′r3′ order.
basis of the sequencing of numerous normal cDNAs,
have been made to this sequence since its publication in
1994. Table 3 shows the organization and splice-junc-
tion sequences of the gene for human PC.
RNA Extraction and Reverse Transcriptase–PCR
(RT-PCR)
Total RNA was extracted from confluent skin fibro-
blasts by use of the Trizol method (Gibco BRL), as out-
lined by the manufacturer. cDNA was generated from
total RNA by reverse transcription using Superscript
II reverse transcriptase (Gibco BRL) and PC-specific
primers.
PC Gene–Mutation Screens
PC sequences were amplified from genomic DNA or
cDNA templates by use of a final 50-ml PCR reaction
composed of 500 ng of each PC-specific primer, 250 mM
each deoxynucleotide triphosphate (dATP, dCTP, dGTP,
and dTTP), 1.5 mM MgCl2, 1 # PCR buffer (Gibco
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Figure 2 PCR-based diagnosis for detection of GrA transition
at nucleotide 1828. A region corresponding to the genomic PC se-
quence (intron 12 to exon 13) was amplified from cultured skin fi-
broblasts by use of forward andmodified reverse primers. Themodified
reverse primer contains two altered residues at nucleotides 1833 (GrT)
and 1835 (TrC), which creates an XmnI restriction site in mutant
DNA (see the Material and Methods section). Lane 1, DNA size
marker. Lanes 2 and 4, Normal Ojibwa PCR product. Lanes 3, 5, and
6, XmnI-digested PCR products from CRM PC-deficient Ojibwa pa-
tients. Lane 7, PCR product from a CRM PC-deficient Micmac pa-
tient. Lane 8, PCR product from a CRM PC-deficient non-Indian
patient. All PCR products shown were subjected to XmnI restriction-
enzyme digestion.
Figure 3 DNA sequence from a small region within the PC gene,
showing the GrT transition at nucleotide 2229. The partial sequence
of intron 13 is also shown. A, Wild-type sequence. B, Sequence from
a PC-deficient Micmac homozygous for the mutation.
BRL), 1% dimethyl sulfoxide, 0.1 mg human genomic
DNA, sterile dH2O to 50 ml total volume, and 2.5 units
of Taq polymerase (Gibco BRL). The polymerase was
generally added in a manual “hot start” after the first
denaturation step (10 min at 94C). The general cycling
parameters were 30–35 cycles of denaturation at 94C
for 0.5–l.0 min, annealing at 55C–66C for 0.5–l.0min,
and extension at 72C for 30 s–l.0 min. A final extension
of 72C for 5–10 min was also included. Cycling param-
eters depended on the melting temperature of each pri-
mer and the length of the PCR product.
The PCR products were screened for mutations either
by thermal cycle sequencing (Amersham) or by sub-
cloning the PCR product into the pCR 2.1 vector (In-
vitrogen), followed by double-stranded dideoxy se-
quencing (Sanger et al. 1977) by use of [35S]-dATP and
the T7 DNA sequencing kit (Pharmacia Biotech). The
sequencing reactions were then separated on a 6% ac-
rylamide gel (Diamed) with constant current of 40 amps
for 2–3 h. Bands were visualized on x-ray film (Kodak).
Diagnostic PCR for the 1828GrA (A610T) Mutation
Genomic DNA corresponding to the region containing
the 1828GrA mutation was PCR amplified by use of
500 ng each of forward (5′-TAT TGG GGC AGA GGC
TTG TGC-3′) and modified reverse (5′-GGA AAG CGC
ATGGCGACG TCAGAAGTGG-3′) oligonucleotides.
The primer set amplifies a 130-bp fragment that, by the
creation of an XmnI restriction-enzyme site, detects the
1828GrA mutation, yielding digestion products of 105
and 25 bp in mutant DNA.
This PCR-based diagnostic method was employed to
screen a population of 72 aboriginal controls fromMan-
itoulin Island, 20 aboriginal controls from the White
Dog Reserve in Ontario, and 20 nonaboriginal controls.
Results
Genomic Structure of the Human PC Gene
Table 3 shows the detailed structure of the gene for
human PC. Exon/intron boundaries were determined by
sequencing of the appropriate regions of human liver or
brain genomic DNA, as described in the Material and
Methods section, and by alignment of these sequences
with the PC cDNA sequence (MacKay et al. 1994). The
gene for the human PC contains 19 exons and 18 in-
trons, spanning ∼16 kb of genomic DNA. As shown in
table 3, the 19 exons range in size from 91 bp (exon
11) to 400 bp (exon 13). The 18 introns range in size
from 79 bp (intron 16) to 3.0 kb (intron 9). Except for
that at the boundary of exon 10 and intron 10, all of
the 5′ donor and 3′ acceptor splice sites at each exon/
intron junction conform to the GT...AG rule and agree
with the consensus sequence compiled for the exon/in-
tron boundaries (Breathnach and Chambon 1981). We
report the cDNA and gene structure with the proximal
rather than the distal promoter elements shown for the
rat as described by Jitrapakdee et al. (1997). We were
not able to find upstream introns several kilobases 5′ to
the initial ATG, as described for the rat PC gene (Jitra-
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Figure 4 Schematic diagram of PC genomic structure, depicting
the location of the two mutations found in the gene. Exons are num-
bered “1”–“19” and are drawn to scale. Also shown are the ATP,
CO2, pyruvate, and biotin-binding domains encoded by the specific
exons.
Figure 5 Comparison of the amino acid sequence of human PC
(H-PC) (MacKay et al. 1994) and other biotin enzymes, including yeast
PC (Y-PC) (Freytag and Collier 1984), rat PC (R-PC) (Jitrapakdee et
al. 1996), the 5S subunit of transcarboxylase (TC-5S) from Propion-
ibacterium shermanii (Kumar et al. 1982), and oxalacetate decarbox-
ylase (OAADC) fromKlebsiella (Wood and Barden 1977).A, Sequence
alignment flanking the alaninerthreonine mutation. Shown are resi-
dues 604–620 of H-PC, 595–611 of Y-PC, 603–619 of R-PC, 65–81
of TC-5S, and 41–57 of OAADC. B, Sequence alignment flanking the
methioninerisoleucine mutation. Shown are residues 732–748 of H-
PC, 718–734 of Y-PC, 732–748 of R-PC, 188–204 of TC-5S, and
162–178 of OAADC.
pakdee et al. 1997). A set of nondistal promoter elements
parallel to the one described in rat may give rise to al-
ternatively spliced 5′ UTR versions of the human PC
mRNA.
The 1828GrA (A610T) Mutation
All CRM PC-deficient patients of Ojibwa and Cree
origin were homozygous for the 1828GrA mutation
(figs. 1 and 2). This mutation changes amino acid 610
from an alanine to a threonine in the pyruvate-binding
domain of the enzyme. As outlined in the Material and
Methods section, several Ojibwa and non-Ojibwa con-
trols were screened by use of the XmnI restriction-digest
test. None of the 72 Ojibwa controls from Manitoulin
Island and none of the 20 nonaboriginal controls ex-
hibited this mutation. Of 40 alleles tested in 20 nonre-
lated control individuals from White Dog, Ontario,
where many cases of PC deficiency originated, 4 were
found to carry the mutation. Although this sample is
not large enough to allow estimation of carrier frequen-
cies, the latter may nevertheless be as high as 1 in 10.
The 2229GrT (M743I) Mutation
Further investigation of the CRM PC-deficient pa-
tients revealed a 2229GrT mutation (fig. 3), which
changes amino acid 743 from a methionine to an iso-
leucine in the carboxylation domain of the enzyme. This
mutation was found only in two Micmac brothers from
Nova Scotia.
Discussion
We have characterized the genomic structure, from the
initial ATG, of the human PC gene and have identified
two point mutations in patients with simple PC defi-
ciency. This is the first report that has identified muta-
tions responsible for PC deficiency.
It has been postulated that biotin carboxylases, in-
cluding PC, evolved through gene fusion, thus leading
to the existence, on one large polypeptide, of three active
sites: the biotinyl domain, the transcarboxylation do-
main, and the biotin carboxylation domain (Obermayer
and Lynen 1976). The biotin-binding lysine of PC, en-
coded by exon 19, is situated 34 amino acids from the
C-terminus within the conserved AMKMmotif common
to most biotin carboxylases (Freytag and Collier 1984;
Lamhonwah et al. 1987; Zhang et al. 1993; MacKay et
al. 1994). The first 500 amino acid residues from the
N-terminus (encoded by exons 1–10), known as the
“transcarboxylation domain,” are responsible for the
ATP-dependent fixation of CO2 into carboxyphosphate
(Lim et al. 1988; Toh et al. 1993). Within this domain,
there are a conserved GGGGRG (amino acids 198–203)
motif that is known to bind ATP (Samols et al. 1988),
and an ERDCSIQRR (amino acids 261–270) motif that
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plays a role in CO2 fixation (Li and Cronan 1992). Exon
13, which codes for the conserved motif WGGA-
TATX5RXLRXLXXPW (amino acids 607–624) and has
32% and 34% identity to transcarboxylase and oxaloac-
etate decarboxylase, respectively, is the segment respon-
sible for holding the substrate pyruvate in place for the
carboxylation reaction (Samols et al. 1988). This motif
is interrupted by intron 12, which is inserted at nucle-
otide 1830 (amino acid 609), whereas all the other cat-
alytically important domains remain intact. All PCs ex-
cept for the enzyme from Pseudomonas citronellolis
have been shown to contain a tightly bound divalent
metal. The enzymes from animal liver contain Mn2,
Mg2, or both, and the enzyme from yeast contains Zn2
(Utter et al. 1975). Exon 14 codes for an HIHTH (amino
acids 769–773) motif that satisfies the convention for
divalent cation binding.
Figure 4 depicts the organization of the exons, the
location of specific domains that the exons encode, and
the positions of the mutations in the gene. The gene is
composed of 19 exons, ranging in size from 91 bp (exon
11) to 400 bp (exon 13) and spans ∼16 kb of genomic
DNA. The amino acid sequence of human PC has 98%
identity with mouse PC and 96% identity with rat PC.
Recently, the rat PC gene structure has been described
(Jitrapakdee et al. 1997). The same group of investi-
gators also has identified two alternative forms of human
PC cDNA in liver (Jitrapakdee et al. 1996), which differ
in their 5′ UTRs but have a common coding region.
These two forms have been designated “hUTR A” (class
I) and “hUTR B” (class II). The hUTR B form corre-
sponds to that described elsewhere by our group
(MacKay et al. 1994), on the basis of their sequence
similarity at the 5′ end. Although all the upstream non-
coding exons of the human PC gene have not yet been
identified, available published sequences (Jitrapakdee et
al. 1996) show no sequence similarities to rat 5′ UTRs.
To further study similarities among the rat and human
PC genes, we compared exon sequences and the posi-
tions of intron/exon boundaries. The exon/intron or-
ganization was highly conserved between rat and hu-
man. Both species of PC contain 19 exons and 18 introns
from the start codon. Comparison of the position of the
introns with the codons of human and rat PC genes
revealed that, in the protein-coding region of the human
gene, phase 0 introns occurred in 11 (61%) of the 18
introns; 5 (28%) of these 18 introns were in phase 1,
and 2 (11%) of these 18 introns were in phase 2. In the
protein-coding region of the rat gene, 16 (89%) of the
18 introns were in phase 0; 2 (11%) of these 18 introns
were in phase 1, and 0 of these 18 introns were in phase
2. Each of the protein-coding exons was comparably
sized in human and rat, with the exception of exon 12,
which, relative to the equivalent exon 13 in the rat gene,
was smaller in human. In the human PC gene, an intron
is located at nucleotide 1827, thus interrupting the exon
portion that encodes the pyruvate-binding domain’s con-
served motif (amino acids 607–624). In the rat PC gene,
the corresponding intron is situated downstream by
∼156 nucleotides, such that this motif remains
uninterrupted.
Both human and rat PC have a large intron between
exons 9 and 10 of human and between exons 10 and
11 of rat, which serves to separate the biotin-carbox-
ylation and -transcarboxylation domains. There is, how-
ever, a significant size difference between the two introns.
The rat intron is ∼10 kb, but in the human form this
intron is only ∼3.0 kb. The size difference of this intron
accounts for the larger size of the rat PC gene relative
to the human version.
The coding exon sequences were in agreement with
the cDNA sequence that we have reported elsewhere
(MacKay et al. 1994). Since that publication, however,
some errors in the sequence have been noted; these are
listed in table A1, in the Appendix.
The mutations that we report here occur in exons 13
and 14, which include the carboxylation domain (exons
13–20) and the pyruvate-binding site. The 1828GrA
missense mutation has the effect of changing amino acid
610 from an alanine to a threonine. The alanine is lo-
cated in a region of homology among yeast, rat, and
human PC, a region that also has homology between
other carboxylases, such as transcarboxylase and ox-
aloacetate decarboxylase (fig. 5A). This segment con-
tains the conserved motif (amino acids 607–624), which
is thought to be a carboxyl-binding element for substrate
binding prior to the carboxylation or decarboxylation
reaction.
The 1828GrA (A610T) mutation was identified in all
13 affected patients of Ojibwa and Cree origin but was
not identified in the two affected Micmac brothers. In-
stead, a 2229GrT transversion mutation was identified
in these two brothers. This mutation is located in exon
14 of the carboxylation domain of the gene, and it alters
amino acid 743, from a methionine to an isoleucine.
This methionine is highly conserved among yeast, rat,
and human PC, as well as among transcarboxylase and
oxaloacetate decarboxylase (fig. 5B). The 1828GrAand
2229GrT mutations are located in both the cDNA and
genomic DNA of the individuals, and both were iden-
tified only in those patients affected with simple PC de-
ficiency. No other mutations were identified in genomic
or cDNA sequences from affected individuals. Whether
these mutations are deleterious to the functioning of the
protein remains to be confirmed, through site-directed
mutagenesis and expression studies.
The 1828GrAmutation is not a polymorphism, since,
of the 72 aboriginal controls from Manitoulin Island
and the 20 nonaboriginal controls, none carried the mu-
tation, as determined by the XmnI diagnostic test. Of
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the 20 aboriginal controls from White Dog Reserve, 4
were carriers, on one of their alleles, of this mutation,
suggesting that, for this group, the allele frequency for
the mutation is possibly as high as 1 in 10. Although
these results partially confirm our hypothesis that a sin-
gle founder mutation might be responsible for PC de-
ficiency in the Algonkian-speaking First Nation groups,
the common mutation is present in all Ojibwa and Cree
PC-deficient patients but is not present in the two Mic-
mac siblings.
Previous studies in our laboratory (Robinson et al.
1983, 1984, 1987), which examined the levels of protein
and mRNA for various patients with the two different
clinical manifestations, showed that the North American
phenotype displayed evidence of [3H]-biotin protein, im-
munoreactive protein corresponding to PC, and mRNA,
on northern blotting. This is consistent with the idea
that the point mutations produce a protein of correct
molecular weight but low expression. In contrast, the
cell lines with complex PC deficiency consistently
showed absence of an mRNA species, absence of im-
munoreactive protein corresponding to PC, and absence
of a biotin-containing polypeptide. If, as is true for the
rat PC gene, there are class I– and class II–type tran-
scripts generated from 5′ UTR exons for human PC, then
this implies that mutations responsible for human PC
deficiency must lie within the coding region of the gene.
We have found that lack of expression in liver and kid-
ney directly correlates with a lack of expression in skin
fibroblasts, implying that the defect lies in a region com-
mon to both transcripts—namely, the coding region. We
believe that the complex phenotype is most likely due
to deletion mutations influencing splice-site junctions ei-
ther between exons and introns in the coding region or,
possibly, within the introns themselves. Our laboratory
is currently investigating these possibilities.
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Appendix
Table A1
Corrections to the cDNA Sequence Published by MacKay et al. (1994)
ORIGINAL CORRECTED
NUCLEOTIDEAmino Acid Codon Amino Acid Codon
385Pro CCC 385Arg CGC 1154
486Asp GAC 486Glu GAG 1458
487Val GTG 487Leu CTG 1459
638Arg CGT 638Pro CCT 1913
727Ala GCT 727Ala GCC 2181
729Ala GCG 729Glu GAG 2186
774Ala GCA 774Asp GAC 2321–2322
775Pro CCG 775Thr ACG 2323
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